Genomic analyses in cancer have been enormously impactful, leading to the identification of
driver mutations and development of targeted therapies. But the functions of the vast majority …

Recent advances in efficiency and ease of implementation have rekindled interest in ion
mobility spectrometry, a technique that separates gas phase ions by their size and shape …

Liquid chromatography (LC) coupled with data-independent acquisition (DIA) mass
spectrometry (MS) has been increasingly used in quantitative proteomics studies. Here, we …

Treatment of severe COVID-19 is currently limited by clinical heterogeneity and incomplete
description of specific immune biomarkers. We present here a comprehensive multi-omic …

The recent technological and computational advances in mass spectrometry-based single-
cell proteomics have pushed the boundaries of sensitivity and throughput. However …

Glioblastoma (GBM) is the most aggressive form of primary brain tumor, for which effective
therapies are urgently needed. Cancer cells are capable of evading clearance by …

The analysis of ultralow input samples or even individual cells is essential to answering a
multitude of biomedical questions, but current proteomic workflows are limited in their …

Glioblastoma, the most aggressive primary brain cancer, has a dismal prognosis, yet
systemic treatment is limited to DNA-alkylating chemotherapies. New therapeutic strategies …

The FragPipe computational proteomics platform is gaining widespread popularity among
the proteomics research community because of its fast processing speed and user-friendly …

The accurate identification and prioritization of antigenic peptides is crucial for the
development of personalized cancer immunotherapies. Publicly available pipelines to …